|
JPS62153300A
(ja)
|
1985-12-26 |
1987-07-08 |
Teijin Ltd |
ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5326856A
(en)
|
1992-04-09 |
1994-07-05 |
Cytogen Corporation |
Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
WO2002043658A2
(en)
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Fcrn-based therapeutics for the treatment of auto-immune disorders
|
|
EP1370288B1
(en)
|
2000-11-20 |
2012-01-11 |
Canadian Blood Services |
Method for treating thrombocytopenia with monoclonal ivig
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2487932A1
(en)
|
2002-05-30 |
2003-12-11 |
Macrogenics, Inc. |
Cd16a binding proteins and use for the treatment of immune disorders
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
AU2004204462B2
(en)
|
2003-01-09 |
2012-03-08 |
Macrogenics, Inc. |
Dual expression vector system for antibody expression in bacterial and mammalian cells
|
|
AU2004204817C1
(en)
|
2003-01-13 |
2011-01-20 |
Macrogenics, Inc. |
Soluble FcyR fusion proteins and methods of use thereof
|
|
CN103040732B
(zh)
*
|
2003-02-10 |
2015-04-01 |
伊兰药品公司 |
免疫球蛋白制剂及其制备方法
|
|
US7662928B2
(en)
|
2003-08-08 |
2010-02-16 |
The Research Foundation Of State University Of New York |
Anti-FcRn antibodies for treatment of auto/allo immune conditions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
WO2006035600A1
(ja)
|
2004-09-30 |
2006-04-06 |
Brother Kogyo Kabushiki Kaisha |
無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
|
|
PA8661401A1
(es)
|
2005-01-28 |
2006-09-08 |
Wyeth Corp |
Formulaciones del liquido polipeptido estabilizado
|
|
JP2008538919A
(ja)
|
2005-04-29 |
2008-11-13 |
ザ ジャクソン ラボラトリー |
ＦｃＲｎ抗体およびその使用
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
MX2009012343A
(es)
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
SI2185589T1
(sl)
|
2007-06-01 |
2016-04-29 |
University Of Maryland Baltimore |
Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
|
|
US8732170B2
(en)
|
2007-11-27 |
2014-05-20 |
Zettics, Inc. |
Method and apparatus for real-time multi-dimensional reporting and analyzing of data on application level activity and other user information on a mobile data network
|
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US8273351B2
(en)
|
2008-04-25 |
2012-09-25 |
Dyax Corp. |
Fc receptor binding proteins
|
|
US20100048488A1
(en)
|
2008-08-01 |
2010-02-25 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
CN103755808B
(zh)
|
2009-03-25 |
2016-02-10 |
霍夫曼-拉罗奇有限公司 |
抗-α5β1抗体及其应用
|
|
PT2477603E
(pt)
|
2009-09-17 |
2016-06-16 |
Baxalta Inc |
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
US20110158987A1
(en)
|
2009-12-29 |
2011-06-30 |
F. Hoffmann-Laroche Ag |
Novel antibody formulation
|
|
BR112013030352B1
(pt)
|
2011-06-02 |
2020-05-19 |
Dyax Corp. |
anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
|
|
US9790280B2
(en)
|
2011-10-26 |
2017-10-17 |
Elanco Tiergesundheit Ag |
Monoclonal canine CD20 antibodies and methods of use
|
|
EP2780463A4
(en)
|
2011-11-18 |
2015-07-01 |
Merck Sharp & Dohme |
FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
EP2847224A4
(en)
|
2012-05-10 |
2016-04-27 |
Zymeworks Inc |
SINGLE ARM MONOVALENT ANTIBODY CONSTRUCTS AND USES THEREOF
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
PL2870247T3
(pl)
|
2012-07-05 |
2019-10-31 |
Hoffmann La Roche |
Układ ekspresji i wydzielania
|
|
MX366425B
(es)
|
2013-03-15 |
2019-07-04 |
Affibody Ab |
Nuevos polipeptidos.
|
|
KR101815265B1
(ko)
|
2013-06-20 |
2018-01-04 |
한올바이오파마주식회사 |
FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
EP3068892A4
(en)
|
2013-11-13 |
2017-05-31 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
EP4053560A1
(en)
|
2013-11-26 |
2022-09-07 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
|
CN106103476B
(zh)
|
2013-12-24 |
2020-11-27 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
US10323066B2
(en)
|
2014-09-17 |
2019-06-18 |
Affibody Ab |
Neonatal Fc receptor binding dimer and methods of use
|
|
JP6853178B2
(ja)
|
2015-01-30 |
2021-03-31 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
ＦｃＲｎ抗体およびその使用方法
|
|
MX386491B
(es)
*
|
2015-03-09 |
2025-03-18 |
argenx BV |
Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
|
|
CA3022547A1
(en)
|
2015-05-12 |
2016-11-17 |
Syntimmune, Inc. |
Humanized affinity matured anti-fcrn antibodies
|
|
GB201508180D0
(en)
*
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2017012959A1
(en)
|
2015-07-17 |
2017-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens
|
|
CN106957365B
(zh)
|
2016-01-11 |
2021-03-16 |
上海交通大学 |
一种单克隆抗体FnAb8及其应用
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
BR112019001806A2
(pt)
|
2016-07-29 |
2019-05-07 |
Momenta Pharmaceuticals, Inc. |
anticorpos para fcrn e métodos de uso dos mesmos
|
|
GB201618424D0
(en)
|
2016-11-01 |
2016-12-14 |
Argenix Bvba |
Treatment of antibody mediated disease
|
|
MA51032A
(fr)
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
|
BR112020011310A2
(pt)
|
2017-12-13 |
2020-11-17 |
Momenta Pharmaceuticals, Inc. |
anticorpos contra fcrn e seus métodos de uso
|
|
JP7486437B2
(ja)
|
2018-06-08 |
2024-05-17 |
アルジェニクス ビーブイ |
免疫性血小板減少症を治療する組成物及び方法
|
|
JP2022505041A
(ja)
|
2018-10-15 |
2022-01-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法
|
|
CN113423426B
(zh)
|
2018-11-06 |
2025-02-18 |
依牧诺万科学有限公司 |
使用抗FcRn抗体治疗格雷夫斯眼病的方法
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3969125A4
(en)
|
2019-05-17 |
2023-01-11 |
Alexion Pharmaceuticals, Inc. |
USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
|
|
BR112021024632A2
(pt)
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
|
|
CA3148826A1
(en)
|
2019-08-01 |
2021-02-04 |
Janssen Biotech, Inc. |
Fcrn antibodies and methods of use thereof
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
JP2023522962A
(ja)
|
2020-04-22 |
2023-06-01 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
Ｐｄ－１アゴニスト多量体結合分子
|
|
CA3200972A1
(en)
|
2020-11-06 |
2022-05-12 |
Momenta Pharmaceuticals, Inc. |
Fcrn antibodies and methods of use thereof
|
|
WO2023012515A2
(en)
|
2021-08-02 |
2023-02-09 |
argenx BV |
Subcutaneous unit dosage forms
|
|
MX2024007806A
(es)
|
2022-01-17 |
2024-07-04 |
argenx BV |
Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos.
|
|
KR20240151809A
(ko)
|
2022-02-21 |
2024-10-18 |
아르젠엑스 비브이 |
Fcrn 길항제를 사용하여 근염을 치료하는 방법
|
|
AU2023260640A1
(en)
|
2022-04-26 |
2024-10-31 |
argenx BV |
Methods for treating bullous pemphigoid using fcrn antagonists
|
|
KR20250037789A
(ko)
|
2022-06-15 |
2025-03-18 |
아르젠엑스 비브이 |
Fcrn/항원-결합 분자 및 사용 방법
|
|
AR130995A1
(es)
|
2022-11-07 |
2025-02-05 |
argenx BV |
Métodos para el tratamiento de nefropatías membranosas primarias mediante el uso de antagonistas de fcrn
|
|
KR20250109193A
(ko)
|
2022-11-07 |
2025-07-16 |
아르젠엑스 비브이 |
Fcrn 길항제를 사용하여 루푸스 신염을 치료하는 방법
|
|
IL320846A
(en)
|
2022-11-14 |
2025-07-01 |
argenx BV |
Fcrn antagonist molecules and methods of use thereof
|
|
WO2024147074A1
(en)
|
2023-01-06 |
2024-07-11 |
argenx BV |
Methods for treating pots using fcrn antagonists
|